(NASDAQ: IMDX) Insight Molecular Diagnostics's forecast annual revenue growth rate of 163.33% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.94%.
Insight Molecular Diagnostics's revenue in 2026 is $1,670,000.On average, 7 Wall Street analysts forecast IMDX's revenue for 2026 to be $45,388,582, with the lowest IMDX revenue forecast at $12,827,919, and the highest IMDX revenue forecast at $103,081,495. On average, 7 Wall Street analysts forecast IMDX's revenue for 2027 to be $235,647,569, with the lowest IMDX revenue forecast at $32,069,798, and the highest IMDX revenue forecast at $408,889,929.
In 2028, IMDX is forecast to generate $909,571,474 in revenue, with the lowest revenue forecast at $808,158,918 and the highest revenue forecast at $1,006,762,597.